Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis
Acta Neuropathologica · 2025
DOI: 10.1007/s00401-025-02892-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2025. Verfasst von Fan Liao und 16 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA. fan.liao@abbvie.com. Hauptthemen laut MEDLINE: Microglia, Amyloid beta-Peptides, Immunotherapy, Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Alzheimer disease (AD) is the most common form of dementia affecting more than 6 million people in the United States. Currently, 3 monospecific antibodies targeting different Amyloid β (Aβ) species have been approved by the US FDA as disease modifying therapeutics for treatment in early AD patients with amyloid pathology. ABBV-916 is a clinical stage human IgG1 monoclonal antibody which binds to N-terminal truncated, pyroglutamate-modified at amino acid position 3, Aβ (AβpE3). The current study characterized ABBV-916 using human tissue samples and amyloid precursor protein (APP) transgenic mice. ABBV-916 selectively bound to recombinant AβpE3-42 fibrils and native amyloid plaques in unfixed AD brain tissue but did not bind targets in human CSF. ABBV-916 significantly reduced dense plaques from brain tissue that were co-cultured with hiPSC-derived phagocytes. In APPPS1-21 mice, ABBV‑916 bound plaques in a dose-dependent manner after a single intravenous injection. In addition, three months of weekly administration of ABBV-916 murine surrogate antibody significantly decreased amyloid plaques in APPPS1-21 mice. In vivo two-photon imaging revealed that the murine version of ABBV-916 inhibited the growth of the plaques in APPPS1-21 mice. ABBV-916 murine surrogate antibody recruited microglia to plaques within 24-48 hours after a single intraperitoneal injection in Cx3cr1-tdTomato/APPPS1-21 mice. Importantly, in contrast to a positive control antibody, ABBV‑916 murine precursor antibody did not cause microhemorrhage in aged APPPS1-21 mice. Taken together, our results suggest that ABBV-916 is a promising drug candidate. Clinical testing is on-going to evaluate the plaque removal and safety profiles of ABBV-916 in AD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA. fan.liao@abbvie.com.
- AbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA.
- AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Zitieren
APA
Liao, F., Calvo-Rodriguez, M., Chhaya, M., Sefrin, J. P., Charych, E. I., Mezler, M., Clausznitzer, D., McGlame, E. J., Zhao, K., Rodgers, A., Cao, Y., Secker, P. F., Fernandez Garcia-Agudo, L., Huang, L., Klein, C., Dellovade, T., & Karran, E. (2025). Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis. Acta Neuropathologica. https://doi.org/10.1007/s00401-025-02892-5
Vancouver
Liao F, Calvo-Rodriguez M, Chhaya M, Sefrin JP, Charych EI, Mezler M, et al. Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis. Acta Neuropathologica. 2025. doi:10.1007/s00401-025-02892-5
BibTeX
@article{Liao2025,
author = {Liao, Fan and Calvo-Rodriguez, Maria and Chhaya, Meha and Sefrin, Julian P and Charych, Erik I and Mezler, Mario and Clausznitzer, Diana and McGlame, Emily J and Zhao, Karen and Rodgers, Allison and Cao, Yang and Secker, Philipp F and Fernandez Garcia-Agudo, Laura and Huang, Lili and Klein, Corinna and Dellovade, Tammy and Karran, Eric},
title = {Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis},
journal = {Acta Neuropathologica},
year = {2025},
doi = {10.1007/s00401-025-02892-5}
}
EUVIMED